## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.1% in lower entry zone (3.0-6.0%), top quartile (76th pct) cross-sectional ranking. Short-term MRS_5 (3.3%) confirms momentum alignment. Strong momentum (+1.6% 5-day acceleration). Outperforming sector by 4.4%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($49.79)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Bristol Myers Squibb’s Opdivo-Plus-Chemotherapy Regimen for Classical Hodgkin Lymphoma Receives FDA Priority Review**
- Source: Oncodaily | 20251212T182054 | Bullish | Relevance: 100%
- Bristol Myers Squibb (NYSE: BMY) announced that the FDA has granted priority review to its supplemental Biologics License Application for Opdivo (nivolumab) plus chemotherapy (AVD) for adults and pediatric patients (12 and older) with previously untreated Stage III or IV classical Hodgkin Lymphoma. The FDA set a PDUFA goal date of April 8, 2026. This decision is based on the positive results from the Phase 3 SWOG S1826 study, aiming to provide a new first-line treatment option for advanced cHL.

**2. Peapack Gladstone Financial Corp Reduces Stock Position in Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20251212T150942 | Neutral | Relevance: 100%
- Peapack Gladstone Financial Corp reduced its stake in Bristol Myers Squibb (BMY) by 4.3%, selling 20,729 shares, while other institutional investors have increased their positions. Bristol Myers Squibb recently reported strong quarterly earnings, beating analyst expectations, and subsequently increased its quarterly dividend to $0.63 per share. The stock currently holds a consensus "Hold" rating from analysts with a target price of $53.83.

**3. Why Bristol-Myers Squibb (BMY) Stock Is Up Today**
- Source: Finviz | 20251212T124500 | Bullish | Relevance: 100%
- Shares of Bristol Myers Squibb (BMY) jumped 2.6% after Guggenheim upgraded the stock to "Buy" with a $62 price target. The positive sentiment was reinforced by the FDA granting priority review to the company’s drug, Opdivo, for classical Hodgkin Lymphoma. Despite this, Morgan Stanley maintained its "Underweight" rating, although it slightly increased its price target.

**4. Quebec becomes first province in Canada to list new subcutaneous OPDIVO® on public drug plan for solid tumour indications**
- Source: BioSpace | 20251212T110758 | Bullish | Relevance: 100%
- Quebec has become the first Canadian province to list OPDIVO® SC (nivolumab for subcutaneous injection) on its public drug plan for authorized solid tumour indications. This new subcutaneous administration offers significant time savings and reduced infusion burden for eligible patients, potentially freeing up 30,000 hours of infusion chair time and 64,000 hours of healthcare professional time across Canada over three years. Bristol Myers Squibb Canada anticipates this will lead to substantial healthcare efficiencies and budget savings for the Canadian healthcare system.

**5. U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma**
- Source: Business Wire | 20251211T120135 | Bullish | Relevance: 100%
- The U.S. Food and Drug Administration (FDA) has granted priority review to Bristol Myers Squibb's supplemental Biologics License Application (sBLA) for their drug Opdivo (nivolumab) in combination with chemotherapy for treating previously untreated Stage III or IV classical Hodgkin Lymphoma in adult and pediatric patients (12 years and older). This decision, based on the Phase 3 SWOG S1826 study, aims to provide a new first-line treatment option, with the FDA assigning a target action date of April 8, 2026. Bristol Myers Squibb believes this Opdivo combination could become a new standard of care, offering meaningful and durable outcomes for patients with this challenging disease.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |
| 2025-12-04 | Scotiabank | $53 | $45 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Scotiabank | main | Sector Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 4 raises (avg +9%) could attract flows.
- Momentum building: MRS_10 improving +1.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (4 raises, avg +9%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $106.7B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 8.7 |
| Current P/E | 8.0 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 2.5% to 4.1% (+1.6% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 76th percentile. MRS_5 at 3.3% confirms short-term momentum alignment. Outperforming sector by 4.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.10% (CS: 76) | Strong |
| RSI_14 | 68.2 | Neutral |
| MACD Histogram | 0.18 | Bullish |
| vs SMA20 | 1.066x | Above |
| vs SMA50 | 1.122x | Above |
| vs SMA200 | 1.071x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $52.41
- **Stop Loss:** $49.79 (5.0% risk)
- **Target:** $56.34 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 381
- **Position Value:** $19,968.21
- **Portfolio %:** 19.97%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*